Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study indicates that obesity-associated systemic IL-6 indirectly enhances pre-adipocyte aromatase expression via increased breast cancer cell PGE2 production.
|
25476497 |
2015 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
|
26515594 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that IL-6 downregulates the tumor suppressor HIC1 and promotes BrCA development in the tumor microenvironment through paracrine or autocrine signaling.
|
31795965 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The beneficial role of SIRT1 activator on chemo- and radiosensitization of breast cancer cells in response to IL-6.
|
31781916 |
2020 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the roles of serum interleukin-6 (IL-6), IL-8, IL-10, squamous cell cancer antigen (SCC-Ag), and cytokeratin 21-1 fragment (CYFRA 21-1) in the metastasis and prognosis of breast cancer.A total of 534 breast cancer patients admitted to our department between January 2011 and December 2014 were enrolled in this study.
|
29245248 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.
|
24467886 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that polymorphisms in IL-6 (-174 G>C) or TNF-alpha (G-238 or G-308) might be associated with prognosis in a subset of patients with high-risk breast cancer.
|
14633738 |
2003 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy.
|
28025102 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
|
29540614 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In human breast cancer MCF-7 cells, sera from maternal HFD-exposed Tg offspring elicited changes in PTEN, BCL2 and IL6 gene expression, mimicking in vivo exposure; increased cell viability and mammosphere formation and induced measures [insulin receptor substrate-1 (IRS-1), IRS-2] of insulin sensitivity.
|
24832086 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy-induced HIF activity enriched the breast cancer stem cell population through interleukin-6 and interleukin-8 signaling and increased expression of multidrug resistance 1.
|
25453096 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study supports a modest association between a variant in IL6 and breast cancer among older women and TNF-related variants and breast cancer among middle-aged women.
|
21523452 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that it may be possible for Evista to emerge as a chemoprevention agent for breast cancer and other cancers such as colon cancer or multiple myeoloma by targeting IL-6/STAT3 signaling.
|
28711499 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CXCL10 secretion was found to be down-regulated by IL-6, a potentially pro-malignant cytokine in breast cancer.
|
15081542 |
2004 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 <i>Trans</i>-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells <i>via</i> Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.
|
29326716 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in ATM, TNF-α and IL6 genes and risk of radiotoxicity in breast cancer patients.
|
30442350 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that MSC-secreted IL-6 and VEGF may act as paracrine factors to sustain breast cancer cell migration.
|
22644871 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Eighty-eight females with breast carcinoma (BC) were studied in this case-control study comparing the cytokine genotypes of TNF-alpha TGF-beta1, IL-10, IL-6, and IFN-gamma with controls.
|
15945506 |
2005 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To attempt to replicate the associations found in our previous study of patients and family caregivers between interleukin 6 (IL6) and nuclear factor kappa beta 2 (NFKB2) and sleep disturbance and to identify additional genetic associations in a larger sample of patients with breast cancer.
|
24012192 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, the effects of IL-6 receptor (IL-6R) on breast cancer aggressiveness and bone metastases were investigated.
|
29557068 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tubulosine exhibited anticancer activity in IL-6-stimulated human breast cancer cells.
|
31598337 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Macrophage conditioned medium (MϕCM) containing elevated levels of cytokines TNF-α, IL-1β and IL-6 had a differential effect on non-invasive (MCF7) and highly invasive (MDA-MB-231) breast cancer cell lines.
|
24705025 |
2014 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We explored transcription mechanisms involved in differential IL-6 gene expression in breast cancer cells with different metastatic properties.
|
19687301 |
2009 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association or trend of association between -174G/C polymorphism of IL-6 gene promoter gene and breast cancer diagnosis or prognosis was shown, even in meta-analyses.
|
19640729 |
2009 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of IL-6 were significantly higher by 2.3-fold in blood cells from breast cancer patients compared with lean control subjects with normal body mass index, and no significant difference was found in the expression level of IL-6 transcripts between overweight/obese and lean control subjects.
|
24961464 |
2014 |